Immune-correlates analysis of an HIV-1 vaccine efficacy trial
BACKGROUND: In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk. METHODS: In pilot studies conducted with RV144 blood...
Saved in:
Similar Items
-
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition
by: Heather A. Prentice, et al.
Published: (2018) -
The thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120
by: Nicos Karasavvas, et al.
Published: (2018) -
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial
by: Shuying S. Li, et al.
Published: (2018) -
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV- 1 subtypes correlate with decreased risk of HIV-1 infection.
by: Zolla-Pazner, Susan, et al.
Published: (2015) -
EU-ASEAN relations : the importance of values, norms and culture
by: Flers, Nicole Alecu de
Published: (2014)